CUE

Cue Biopharma, Inc. CUE

NasdaqSmall CapHealthcare

13F Pro quality score

Rank #2,547 of 2,925

Why it scores 28Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$7.88M

Quarter to Jun 30

Net income

$-153.07M

Quarter to Jun 30

Free cash flow

$-29.00M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$52.25M total
Bleichroeder LP
$11.70M-94.6%
DRIEHAUS CAPITAL MANAGEMENT LLC
$9.22MNew
VANGUARD CAPITAL MANAGEMENT LLC
$5.10M-93.4%
Ikarian Capital, LLC
$3.29MNew
TFG Asset Management GP Ltd
$2.96MNew
StemPoint Capital LP
$2.11MNew
BlackRock, Inc.
$1.82M-87.1%
ADAR1 Capital Management, LLC
$1.74MNew
Lion Point Capital, LP
$1.67M-97.6%
Squadron Capital Management LLC
$1.58MNew
DIADEMA PARTNERS LP
$1.53M-63.4%
GEODE CAPITAL MANAGEMENT, LLC
$1.51M-95.5%
BOOTHBAY FUND MANAGEMENT, LLC
$992.8KNew
UBS Group AG
$842.7K-69.8%
CITADEL ADVISORS LLC
$809.0KNew
VANGUARD FIDUCIARY TRUST CO
$772.5K-95.5%
Texas Capital Bank Wealth Management Services Inc
$722.1K-94.2%
RENAISSANCE TECHNOLOGIES LLC
$463.6K-93.1%
STATE STREET CORP
$447.4K-92.1%
Persistent Asset Partners Ltd
$389.2K-63.0%
Robertson Stephens Wealth Management, LLC
$351.4K-97.7%
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$347.3K-55.3%
Seven Fleet Capital Management LP
$337.8KNew
NORTHERN TRUST CORP
$287.9K-90.4%
ADVISORY RESEARCH INC
$270.6K-96.7%
See all 50 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/CUE

Earnings Per Share

13fpro.ai/company/CUE

Loading ratio trend…

CUE key financials by period

Reported revenue, net income and operating margin by fiscal year, from Cue Biopharma, Inc.'s annual filings on SEC EDGAR.

Cue Biopharma, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$27.5M$-26.6M-96.7%
FY 2024$9.3M$-40.7M—
FY 2023$5.5M$-50.7M—
FY 2022$1.2M$-53.0M—
FY 2021$14.9M$-44.2M—
FY 2020$3.2M$-44.8M—
Source: CUE filings on SEC EDGAR →

Companies similar to CUE

Ranked by quality-factor profile and overlapping institutional ownership, from the latest 13F filings and SEC financials.

CUE insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Cue Biopharma, Inc. (CUE): stock profile, AI score and financials

Cue Biopharma, Inc. (CUE) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CUE at 27.6/100 on a composite quality score built from its SEC filings, placing it at rank #2,547 of 2,925 stocks — the bottom half of the AI-ranked universe. CUE scores in the top quartile across revenue growth (94.8). Areas of concern include profitability (2.6) and revenue scale (3.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 10.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Cue Biopharma, Inc. reports quarterly revenue of $7.9M, net income of $-153.1M, free cash flow of $-29.0M. Top institutional holders of CUE by reported 13-F value include Bleichroeder, DRIEHAUS CAPITAL MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. CUE trades on the Nasdaq exchange and files with the SEC under CIK 1645460. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CUE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cue Biopharma, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1645460 →